Skip to content
‹ Back to IndustriesSciences

Advocating for the Scientific Community Through Media

On the Space to Grow podcast, Astroscale’s Chris Blackerby and Charity Weeden bring their compelling experience and expertise to map out the technology, international policy, and scalability that will define the next generation of space exploration.   Looking at all aspects of the world of space and science is the crux of Space to Grow. It’s time to look at the human…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Chris Blackerby · · AstroscaleCharity Weeden PodcastChris Blackerby PodcastEducation
Share

Key takeaways

01

On the Space to Grow podcast, Astroscale’s Chris Blackerby and Charity Weeden bring their compelling experience and expertise to map out the technology, international policy, and scalability that will define the next generation of space exploration.

02

Looking at all aspects of the world of space and science is the crux of Space to Grow.

03

It’s time to look at the human…

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

On the Space to Grow podcast, Astroscale’s Chris Blackerby and Charity Weeden bring their compelling experience and expertise to map out the technology, international policy, and scalability that will define the next generation of space exploration.

Looking at all aspects of the world of space and science is the crux of Space to Grow. It’s time to look at the human and storytelling aspect of science and space. Hosts Chris Blackerby and Charity Weeden of Astroscale welcomed MIT Engineer and Emmy-nominated science TV host Emily Calandrelli to the podcast. Calandrelli is a prominent member of the science communications ecosystem and shared her own story and insights on storytelling in science.

Becoming an engineer wasn’t a lifelong dream for Calandrelli—her drive was purely practical until discovering the technology and policy program in grad school at MIT. “It was looking at science and technology through a policy lens and asking about if it’s ethical, the role of government, and keeping the public safe. I thought these were fascinating questions,” she said.

That experience shifted her career to be more policy and communications driven. She intended to work in DC but got a call from a production company asking her if she wanted to host a TV show about space.

Years later, she’s a strong voice for the scientific community and advocates for people with all different talents to get involved in the space industry. “There are other ways to get involved in space outside of STEM,” she added.

Those types of roles are now trying to spread scientific literary and combat misinformation. Calandrelli focuses her approach on the human side of the story. She explained, “Going to the real human emotions attached to the story matters. You can frame an argument based on what the audience cares about and find simple, creative ways to explain science.”

Science is complex and uncertain, especially the coronavirus. In communicating a difficult and uncertain event, Calandrelli sees that science communication is challenging. “Everyone’s learning how to communicate this uncertainty, but there’s a lot of false information out there. It’s important to learn from the right sources,” she said.

Listen to Previous Episodes Here!

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

CB
Chris Blackerby
B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Sciences Insights

Photonic AI hardware is now in outside testers' hands

Photonic AI hardware is now in outside testers' hands

Kopin is expanding microLED manufacturing in Westborough, Massachusetts, which could add up to 80 jobs over five years. Its microLEDs will go to military displays and to Neural I/o, an interconnect that sends AI data as light. In the same news round-up, Q.ANT and IONOS opened a photonic processor pilot where approved applicants can run their own workloads.

  • 01Two photonic approaches tied to AI’s power problem reached testable hardware this month: PsiQuantum’s 8×8 optical switch samples and Q.ANT’s second-generation processor via an IONOS bare-metal pilot in Germany.
  • 02PsiQuantum is sending samples of an 8×8 demonstration optical circuit switch to selected prospective customers, giving buyers hardware they can test even though commercial products and full specs are still pending.
  • 03Staffing may not keep up with demand: a 2023 Applied Optics study projected US demand for 42,000 new middle-skilled photonics workers by 2030, and expansions like Kopin's could draw from that same pool.

Nov 15, 2026

Lilly breaks ground on a $5B Virginia bioconjugate plant and expects its first building to open in 2030

Lilly breaks ground on a $5B Virginia bioconjugate plant and expects its first building to open in 2030

Eli Lilly held a groundbreaking on Oct. 22 for a $5 billion manufacturing plant in Goochland County, Virginia. The company expects the first building to open in 2030. Lilly has also committed $40 million to the Virginia Center for Advanced Pharmaceutical Manufacturing, a statewide workforce development network that brings together industry, government and higher education partners. The network's plans include a pilot-scale training center in Goochland County, slated to open in 2028. That timing could let workers start training before the plant begins production.

  • 01Goochland’s pilot-scale training center is slated to open in 2028, two years before Lilly expects its first production building in 2030—signaling workforce readiness as the earliest milestone at Lilly’s first dedicated, fully integrated API and drug product facility for its bioconjugate platform and monoclonal antibody portfolio.
  • 02For anyone tracking new ADC supply, Goochland is a later story: Lilly expects to open the first building in 2030 and the second in 2031.

Nov 15, 2026

Celliaz is betting on one AAV2 vector for an eye disease with 90-plus gene causes

Celliaz is betting on one AAV2 vector for an eye disease with 90-plus gene causes

Andelyn Biosciences will develop and manufacture CLZ002, Celliaz’s investigational AAV2 gene therapy for retinitis pigmentosa, supporting IND-enabling studies and a planned Phase 1/2 trial. CLZ002 targets a retinal repair mechanism rather than specific mutations. If it works as intended, one manufacturing process could serve patients across many genetic causes of the disease.

  • 01Retinitis pigmentosa can arise from mutations in more than 90 genes; CLZ002 targets a retinal repair mechanism, and if it works as intended one AAV2 manufacturing process could serve patients that gene-specific programs would split into many products.
  • 02For a pre-IND sponsor, putting plasmid and viral vector production with one CDMO can mean fewer handoffs, and the questions worth settling early are who owns the process built on a proprietary platform and how it would move if needed.

Nov 14, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

CB
Chris Blackerby

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512